Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.70 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672449 | 0.85 | GPR119 (0.67) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL288892 | 0.83 | GPR119 (1.00) | GPR119 | |
| SCHEMBL386244 | 0.83 | GPR119 (0.79) | GPR119 | |
| SCHEMBL390094 | 0.82 | GPR119 (0.71) | GPR119 | |
| SCHEMBL4719718 | 0.81 | GPR119 (0.79) | GPR119 | |
| SCHEMBL4719030 | 0.81 | GPR119 (0.67) | GPR119 | |
| SCHEMBL3967006 | 0.81 | GPR119 (0.63) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL386720 | 0.80 | GPR119 (0.70) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL392046 | 0.79 | GPR119 (0.67) | GPR119CCNA2CDK2CDK5CDK5R1 | |
| SCHEMBL391589 | 0.79 | GPR119 (0.69) | GPR119CCNA2CDK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |